depression
Published research on depression.
According to the World Health Organization (WHO), depression is projected to become the number one global disease burden by 2030. Present-day statistics suggest that depression affects over …
Read article →Most pharmacological-based treatments for depression aim to increase levels of various neurotransmitters, particularly serotonin (5-HT). It is thought that approximately 2 out of 3 individua…
Read article →Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia. Several years later in 2009, a longer-acting format of the medication called “Invega S…
Read article →Fanapt (Iloperidone) is an atypical antipsychotic that was approved by the FDA on May 6, 2009 for the treatment of schizophrenia. The drug is thought to have been synthesized in the 1990s, d…
Read article →Despite the fact that pharmaceutical companies continue to promote the concept of “chemical imbalances” as the root cause of depression, this is a vast oversimplification of an infinitely mo…
Read article →It seems as though society is on the verge of ushering in a new generation of treatment modalities for depression and other psychiatric conditions. While most people turn to pharmaceutical d…
Read article →Saphris (Asenapine) is a drug that was approved by the FDA in 2007 for the treatment of schizophrenia and the manic phases of bipolar disorder. It functions by acting primarily on 5-HT2A ser…
Read article →